000075503 001__ 75503
000075503 005__ 20200117221646.0
000075503 0247_ $$2doi$$a10.1016/S0167-8140(18)32535-0
000075503 0248_ $$2sideral$$a107941
000075503 037__ $$aART-2018-107941
000075503 041__ $$aeng
000075503 100__ $$aMendez Villamon, A.
000075503 245__ $$aToxicity results after treatment with Electronic Brachytherapy in patients with endometrial cancer
000075503 260__ $$c2018
000075503 5060_ $$aAccess copy available to the general public$$fUnrestricted
000075503 5203_ $$aPoster Session [EP-2226]
Purpose or Objective To analyse the toxicity outcomes after treatment with Electronic Brachytherapy (XB) in postsurgical endometrial cancer patients treated at our medical centre. Material and Methods Prospective study in which we selected 94 patients, between September/2015 and September/2017, that received treatment with XB administered twice a week after endometrial cancer surgery, with IMRT planificati on. The patients were divided in two groups: Group 1 (57/94) considered high risk received external beam radiotherapy (46Gy) followed by XB (15Gy in 5Gy fractions) and group 2 (37/94) considered intermediate risk received exclusive XB (25Gy in 5Gy fraction s). We analysed the median dose in bladder, rectum and sigmoid D2cc, V50, V35 with XB comparing the doses with Ir192. The vaginal mucosa, gastrointestinal (GI) and genitourinary (GU) toxicities were analysed with the Common Terminology Criteria for Adverse Events (CTCAE 4.0) scale. Results The median dose in bladder with XB vs. Ir192 was: 2cc 62.9 vs. 69.9%, V50 7.1 vs. 12.6Gy, V35 15 vs. 28.1. In rectum XB vs. Ir192 was: D 2cc 64.01% vs. 67.7%, V50 7.8 vs. 10.9Gy, V35 16.5 vs. 31.8Gy. In sigmoid XB vs. Ir 192 was: D 50.37%vs. 58.0%, V50 8.8 vs. 16.2Gy, V35 21.2 vs. 37.5Gy. The median follow- up was 11 months (range 1 - 23, 9 months). In group 1, acute vaginal mucositis (G1) was observed in 35.08% of the patients, GI toxicity (G1) in 5.26% and GU toxicity (G1) in 10.52%. In group 2, we observed acute vaginal mucositis G1 in 45% of the patients and G2 in 10.81%, GI toxicity (G1) occurred in 2.7% and GU toxicity (G1) was present in 16.21%. There was no grade 3 or greater toxicity in any of the groups. Late toxici ty was observed in only 4 patients: Mucositis (G1) in 3 patients and GU toxicity (G1) in 1 patient. Conclusion The dose received by the organs at risk with the XB is less compared to Ir192, with a good coverage of the PTV. The greater toxicity was observe d immediately after the treatment was finished with an important reduction of the symptoms after 6 months. This technique shows excellent results as for toxicity.
000075503 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000075503 590__ $$a5.252$$b2018
000075503 591__ $$aRADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING$$b14 / 129 = 0.109$$c2018$$dQ1$$eT1
000075503 591__ $$aONCOLOGY$$b46 / 229 = 0.201$$c2018$$dQ1$$eT1
000075503 592__ $$a2.023$$b2018
000075503 593__ $$aHematology$$c2018$$dQ1
000075503 593__ $$aRadiology, Nuclear Medicine and Imaging$$c2018$$dQ1
000075503 593__ $$aOncology$$c2018$$dQ1
000075503 655_4 $$ainfo:eu-repo/semantics/conferenceObject$$vinfo:eu-repo/semantics/publishedVersion
000075503 700__ $$aMiranda Burgos, A.
000075503 700__ $$aGascon Ferrer, M.
000075503 700__ $$aPuertas Valino, M.
000075503 700__ $$aCordero, S.L.
000075503 700__ $$aMartinez, A.G.
000075503 700__ $$aQuintana, I.N.
000075503 700__ $$aMuñoz Saenz, E.
000075503 700__ $$aRiazuelo Fantova, G.R.
000075503 700__ $$aEscartín Martinez, I.
000075503 700__ $$aGomez, J.F.
000075503 700__ $$aIbañez Carreras, R.$$uUniversidad de Zaragoza
000075503 700__ $$aTejedor Gutierrez, M.
000075503 7102_ $$11010$$2770$$aUniversidad de Zaragoza$$bDpto. Pediatría Radiol.Med.Fís$$cÁrea Radiol. y Medicina Física
000075503 773__ $$g127, Suppl. 1 (2018), S1230-S1231$$pRadiother. oncol.$$tRADIOTHERAPY AND ONCOLOGY$$x0167-8140
000075503 8564_ $$s826779$$uhttps://zaguan.unizar.es/record/75503/files/texto_completo.pdf$$yVersión publicada
000075503 8564_ $$s86803$$uhttps://zaguan.unizar.es/record/75503/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000075503 909CO $$ooai:zaguan.unizar.es:75503$$particulos$$pdriver
000075503 951__ $$a2020-01-17-22:06:55
000075503 980__ $$aARTICLE